Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an update.
RemeGen Co., Ltd. announced that its drug, disitamab vedotin, has received marketing approval in China for treating HER2-positive advanced breast cancer with liver metastasis. This approval, based on a Phase III clinical study, marks a significant advancement in treatment options for this aggressive cancer type, potentially impacting the company’s market position and offering new hope for patients with limited treatment options.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a pharmaceutical company based in China, specializing in the development of innovative antibody-drug conjugates (ADCs) targeting cancer treatment. The company focuses on creating drugs that target specific proteins on tumor cells, with products that have gained recognition for their clinical value in treating various cancers, including gastric and uroepithelial carcinoma.
Average Trading Volume: 7,948,766
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.63B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.